Table 1 Demographics and baseline characteristics for patients

	Phase 1b		Phase 2a
Property	Number of patients	Percentage, %	Number of patients	Percentage, %
Sex [1]
Female	14	61	12	33
Male	22	39	24	67
Age (years)
Median	74.5 (Range 51-85)		76 (Range 66–86)
<75	18	50	12	33
≥75	18	50	24	67
ECOG at screening
Median	1 (Range 0–2)		1 (Range 0–2)
0	7	19	13	36
1	19	53	18	50
2	10	28	5	14
Type of cancer
AML	34	94	36	100
MDS (high risk)	2	6	0	0
% blasts at screening (bone marrow)
<10	4	11	5	14
≥10	26	72	31	86
missing	6	17	0	0
Cytogenetic Profile [2]
favorable	2	6	7	19
intermediate	3	8	13	36
adverse	7	19	14	39
missing	24	67	2	6
Disease status
Treatment-naive	2	6	6	17
relapsed	16	44	21	58
refractory	12	33	9	25
other	6	17	0	0
No. lines prior therapy
Median	2 (Range 1–6)		1 (Range 0–8)
0	1	3	6	17
1	12	33	15	42
2	11	31	9	25
≥3	12	33	6	17
Prior treatment
Venetoclax	0	0	11	31
Allo-HCT	2	6	0	0
Intensive chemotherapy	18	50	9	25
FLT3 status
Wildtype	17	47	21	58
Mutated	7	19	5	14
of which ITD	2	6	1	3
Missing	12	33	10	28

Allo-HCT Allogeneic hematopoietic cell transplantation, AML Acute Myeloid leukemia, ECOG Eastern Cooperative Oncology Group performance status, ITD internal tandem duplication, MDS Myelodysplastic syndrome, No. number. Headings and subheadings in bold.
[1] Self-reported.
[2] Cytogenetic risk was assessed by each study site using locally defined criteria. DE cohort patients were assessed as low, medium or high risk. LDAC Cohort patients were assessed as favorable, intermediate or adverse risk. Where specific data was provided, classification was consistent with ELN 2017 criteria.

Quick links

Search